Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Incidence and Prognosis of Heart Valve Embolization

The incidence of peri-procedural transcatheter heart valve embolization and migration (TVEM) is as low as 1%. However, it is associated with increased morbidity and mortality.

Trombólisis local en tromboembolismo pulmonar

Peri-procedural TVEM is one of the most feared complication given its potential to transform the procedure into a catastrophe, but little do we know about its incidence (except for a few reports from one single center) or, more importantly, its impact in patient prognosis. 

This study recently published in the European Heart Journal sheds some light on this event, since it assessed a large cohort of patients treated in 26 internationally renowned centers.

Between 2010 and 2017 TVEM occurred in 273 patients (0.92% of the entire cohort), 217 to the ascending aorta and 56 to the left ventricle. The use of the self-expandable prosthesis, 1st gen devices and bicuspid valves were the independent predictors of TVEM.


Read also: Trying to Reduce Post TAVR Kidney Injury.


Bail-out maneuvers to prevent a definite catastrophe included the use of snares (41%), implanting a second valve (83.2%) and conversion to surgery (19%).

Using propensity score, researchers were able to match 1:4 a cohort of 235 patients presenting TVME and another cohort of 932 patients who did not present TVME. The first group showed increased all-cause mortality at 30 days (18.6% vs 4.9%; p<0.001) and one year (30.5% vs. 16.6%; p<0.001). Something similar happened with stroke at 30 days (10.6% vs. 2.8%; p<0.001), but not at one year. 

The need for emergency cardiovascular support, major stroke at 30 days and kidney injury increased mortality risk at one year, while a good kidney function at baseline was protective. 

Conclusion

Peri-procedural TVME has around 1% incidence and is associated with significant mortality and morbidity incresase.

Original title: Incidence and outcome of peri-procedural transcatheter heart valve embolization and migration: the TRAVEL registry (TranscatheteR HeArt Valve EmboLization And Migration).

Reference: Won-Keun Kim et al. European Heart Journal (2019) 40, 3156–3165.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

TAVI in TAVI: Clinical and Hemodynamic Outcomes According to the Type of Prosthesis Used in TAVI-in-TAVI

With the expansion of TAVI to younger and lower surgical risk patients, bioprosthetic valve degeneration and the need for repeat interventions are expected to...

Percutaneous Closure of Patent Foramen Ovale in Patients Over 60 Years Old With Cryptogenic Stroke: A Safe and Effective Strategy?

Cryptogenic stroke accounts for up to one-third of all ischemic strokes and remains strongly associated with the presence of a patent foramen ovale (PFO),...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...